Division of Endocrinology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Republic of Korea.
Severance Institute for Vascular and Metabolic Research, Yonsei University College of Medicine, Republic of Korea.
J Diabetes Res. 2022 Feb 22;2022:9537741. doi: 10.1155/2022/9537741. eCollection 2022.
Several experimental studies have suggested beneficial effects of on glucose metabolism. However, there has been no human study assessing the effects of on glucose metabolism. Therefore, we investigated whether improves glucose control and insulin resistance in type 2 diabetes patients.
Ninety patients diagnosed with type 2 diabetes (T2DM) for more than 6 months were enrolled. Subjects were randomly divided into placebo ( = 45) or ( = 45) groups and then assigned to take placebo or capsules (500 mg/capsule) for a 12-week intervention period. Biochemical markers, including fasting glucose, 2-hour postprandial plasma glucose, and lipid profile levels, as well as insulin, c-peptide, and Hba1c, were measured. Furthermore, insulin sensitivity indices, such as HOMA-IR, HOMA-beta, and QUICKI, were assessed before and after the 12-week administration.
Eighty-four patients completed the study. There were no significant differences in fasting, postprandial glucose, HbA1c, or lipid parameters. HOMA-IR and QUICKI indices were improved at week 12 in the group, especially in subjects with HOMA-IR of 1.8 or more ( < 0.05). Fasting, postprandial c-peptide, and insulin levels decreased at week 12 in the group ( < 0.05). These significant differences were not observed in the placebo group.
Twelve-week administration of in T2DM patients resulted in significant improvement in insulin resistance, especially in those with lower insulin sensitivity. A larger population study with a longer follow-up period and an effort to elucidate the mechanism is warranted to further assess the effects of on T2DM patients.
几项实验研究表明[药物名称]对葡萄糖代谢有益。然而，目前还没有人类研究评估[药物名称]对葡萄糖代谢的影响。因此，我们研究了[药物名称]是否改善 2 型糖尿病患者的血糖控制和胰岛素抵抗。
共纳入 90 例诊断为 2 型糖尿病（T2DM）超过 6 个月的患者。患者随机分为安慰剂（n=45）或[药物名称]（n=45）组，然后分别服用安慰剂或[药物名称]胶囊（500mg/胶囊）12 周。测定空腹血糖、餐后 2 小时血糖和血脂谱水平以及胰岛素、C 肽和 Hba1c 等生化标志物，并在 12 周治疗前后评估胰岛素敏感性指数，如 HOMA-IR、HOMA-β和 QUICKI。
84 例患者完成了研究。空腹、餐后血糖、HbA1c 或血脂参数无显著差异。12 周时，[药物名称]组 HOMA-IR 和 QUICKI 指数改善，尤其是 HOMA-IR 为 1.8 或更高的患者（<0.05）。[药物名称]组在第 12 周时空腹、餐后 C 肽和胰岛素水平下降（<0.05）。安慰剂组未观察到这些显著差异。
12 周[药物名称]治疗 T2DM 患者可显著改善胰岛素抵抗，尤其是胰岛素敏感性较低的患者。需要进行更大规模的人群研究和更长时间的随访，以阐明其机制，进一步评估[药物名称]对 T2DM 患者的影响。
